Payment overview · 2025
General Payments
$63.40
3 reported records · 2 companies
Healthcare provider profile · identity verified
Connie Walker Richardson, MD
Allopathic & Osteopathic Physicians|Family Medicine · CENTREVILLE, AL · NPI 1093815722
Verified facts
What the public records show
CMS Open Payments records show Connie Walker Richardson, MD received $63.40 in general payments during 2025 across 3 reported records.
Novo Nordisk Inc accounted for 61.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.74 | 61.1% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $24.66 | 38.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $63.40 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 390 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 355 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 340 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 292 | 74 |
| Potassium Chloride | Potassium Chloride | 292 | 48 |
| Omeprazole | Omeprazole | 275 | 64 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 245 | 49 |
| Atorvastatin Calcium | Atorvastatin Calcium | 233 | 60 |
| Tramadol Hcl | Tramadol Hcl | 225 | 51 |
| Trazodone Hcl | Trazodone Hcl | 207 | 35 |
| Lisinopril | Lisinopril | 194 | 48 |
| Losartan Potassium | Losartan Potassium | 187 | 42 |
| Furosemide | Furosemide | 179 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 163 | 24 |
| Donepezil Hcl | Donepezil Hcl | 150 | 23 |
| Sertraline Hcl | Sertraline Hcl | 147 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 135 | 29 |
| Metformin Hcl | Metformin Hcl | 128 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 22 |
| Carvedilol | Carvedilol | 116 | 20 |
| Montelukast Sodium | Montelukast Sodium | 110 | 25 |
| Allopurinol | Allopurinol | 106 | 14 |
| Famotidine | Famotidine | 105 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 24 |
| Eliquis | Apixaban | 101 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 97 | 78 |
| Methocarbamol | Methocarbamol | 95 | 49 |
| Lorazepam | Lorazepam | 94 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 28 |
| Ozempic | Semaglutide | 93 | 20 |
| Simvastatin | Simvastatin | 92 | 31 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 89 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 24 |
| Cephalexin | Cephalexin | 82 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 11 |
| Alprazolam | Alprazolam | 79 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 36 |
| Prednisone | Prednisone | 77 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 23 |
| Meloxicam | Meloxicam | 74 | 31 |
| Clonazepam | Clonazepam | 67 | suppressed |
| Mounjaro | Tirzepatide | 67 | 13 |
| Azithromycin | Azithromycin | 62 | 56 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 61 | 22 |
| Ondansetron Odt | Ondansetron | 61 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 35 |
| Cefdinir | Cefdinir | 54 | 44 |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Pregabalin | Pregabalin | 51 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | 11 |
| Buspirone Hcl | Buspirone Hcl | 49 | suppressed |
| Nystatin | Nystatin | 49 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 24 |
| Latanoprost | Latanoprost | 47 | suppressed |
| Bumetanide | Bumetanide | 46 | suppressed |
| Fluconazole | Fluconazole | 45 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 15 |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 11 |
| Glimepiride | Glimepiride | 43 | 11 |
| Glipizide | Glipizide | 43 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 41 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 38 |
| Solifenacin Succinate | Solifenacin Succinate | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 21 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Klor-Con M20 | Potassium Chloride | 38 | suppressed |
| Roflumilast | Roflumilast | 38 | suppressed |
| Amoxicillin | Amoxicillin | 37 | 35 |
| Chlorthalidone | Chlorthalidone | 37 | 13 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 37 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Fentanyl | Fentanyl | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Mupirocin | Mupirocin | 30 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 14 |
| Lactulose | Lactulose | 26 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 23 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Klor-Con 10 | Potassium Chloride | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 19 |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 18 | 18 |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 11 |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $63.40 · 3 records | Novo Nordisk Inc | INGREZZA, Ozempic, Rybelsus, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error